Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92,189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.
Moriyama T, Nishii R, Perez-Andreu V, Yang W, Klussmann FA, Zhao X, Lin TN, Hoshitsuki K, Nersting J, Kihira K, Hofmann U, Komada Y, Kato M, McCorkle R, Li L, Koh K, Najera CR, Kham SK, Isobe T, Chen Z, Chiew EK, Bhojwani D, Jeffries C, Lu Y, Schwab M, Inaba H, Pui CH, Relling MV, Manabe A, Hori H, Schmiegelow K, Yeoh AE, Evans WE, Yang JJ. Moriyama T, et al. Among authors: li l. Nat Genet. 2016 Apr;48(4):367-73. doi: 10.1038/ng.3508. Epub 2016 Feb 15. Nat Genet. 2016. PMID: 26878724 Free PMC article.
Preclinical evaluation of NUDT15-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy.
Nishii R, Moriyama T, Janke LJ, Yang W, Suiter CC, Lin TN, Li L, Kihira K, Toyoda H, Hofmann U, Schwab M, Takagi M, Morio T, Manabe A, Kham S, Jiang N, Rabin KR, Kato M, Koh K, Yeoh AE, Hori H, Yang JJ. Nishii R, et al. Among authors: li l. Blood. 2018 May 31;131(22):2466-2474. doi: 10.1182/blood-2017-11-815506. Epub 2018 Mar 23. Blood. 2018. PMID: 29572377 Free PMC article.
Massively parallel variant characterization identifies NUDT15 alleles associated with thiopurine toxicity.
Suiter CC, Moriyama T, Matreyek KA, Yang W, Scaletti ER, Nishii R, Yang W, Hoshitsuki K, Singh M, Trehan A, Parish C, Smith C, Li L, Bhojwani D, Yuen LYP, Li CK, Li CH, Yang YL, Walker GJ, Goodhand JR, Kennedy NA, Klussmann FA, Bhatia S, Relling MV, Kato M, Hori H, Bhatia P, Ahmad T, Yeoh AEJ, Stenmark P, Fowler DM, Yang JJ. Suiter CC, et al. Among authors: li ck, li ch, li l. Proc Natl Acad Sci U S A. 2020 Mar 10;117(10):5394-5401. doi: 10.1073/pnas.1915680117. Epub 2020 Feb 24. Proc Natl Acad Sci U S A. 2020. PMID: 32094176 Free PMC article.
Identification of small molecules that mitigate vincristine-induced neurotoxicity while sensitizing leukemia cells to vincristine.
Diouf B, Wing C, Panetta JC, Eddins D, Lin W, Yang W, Fan Y, Pei D, Cheng C, Delaney SM, Zhang W, Bonten EJ, Crews KR, Paugh SW, Li L, Freeman BB 3rd, Autry RJ, Beard JA, Ferguson DC, Janke LJ, Ness KK, Chen T, Zakharenko SS, Jeha S, Pui CH, Relling MV, Eileen Dolan M, Evans WE. Diouf B, et al. Among authors: li l. Clin Transl Sci. 2021 Jul;14(4):1490-1504. doi: 10.1111/cts.13012. Epub 2021 May 31. Clin Transl Sci. 2021. PMID: 33742760 Free PMC article.
Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication.
Inaba H, van Oosterwijk JG, Panetta JC, Li L, Buelow DR, Blachly JS, Shurtleff S, Pui CH, Ribeiro RC, Rubnitz JE, Pounds S, Baker SD. Inaba H, et al. Among authors: li l. Clin Cancer Res. 2022 Jun 13;28(12):2536-2546. doi: 10.1158/1078-0432.CCR-21-4450. Clin Cancer Res. 2022. PMID: 35344039 Free PMC article.
Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies.
Inaba H, Panetta JC, Pounds SB, Wang L, Li L, Navid F, Federico SM, Eisenmann ED, Vasilyeva A, Wang YD, Shurtleff S, Pui CH, Gruber TA, Ribeiro RC, Rubnitz JE, Baker SD. Inaba H, et al. Among authors: li l. Clin Cancer Res. 2019 Dec 15;25(24):7320-7330. doi: 10.1158/1078-0432.CCR-19-0470. Epub 2019 Aug 27. Clin Cancer Res. 2019. PMID: 31455680 Free PMC article.
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Inaba H, Rubnitz JE, Coustan-Smith E, Li L, Furmanski BD, Mascara GP, Heym KM, Christensen R, Onciu M, Shurtleff SA, Pounds SB, Pui CH, Ribeiro RC, Campana D, Baker SD. Inaba H, et al. Among authors: li l. J Clin Oncol. 2011 Aug 20;29(24):3293-300. doi: 10.1200/JCO.2011.34.7427. Epub 2011 Jul 18. J Clin Oncol. 2011. PMID: 21768474 Free PMC article. Clinical Trial.
92,189 results
You have reached the last available page of results. Please see the User Guide for more information.